


# Turning the tide against TB

## An increasingly robust portfolio



## Our current investments include



### Preventive treatment including long-acting formulations

for people with latent TB, such as children and people living with HIV

**\$ 60 m**



### Better treatments

halving treatment time for all forms of resistant tuberculosis; improved TB and MDR-TB treatment for children; and helping patients succeed in TB treatment through digital adherence technologies

**\$ 115 m**



### Strengthening TB diagnosis

detecting TB in children early; bringing high-tech tests for fast and accurate diagnosis of drug-resistant TB; integrating TB screening with other health services such as HIV, nutrition, maternal and child health

**\$65 m**



### Our TB portfolio keeps growing

with investments on track to hit US\$ 300 million in 2020